Orchid Pharma and Orchid Bio Pharma signs MoU to obtain license for 7ACA technology
Capital Market Orchid Pharma and its wholly owned subsidiary, Orchid Bio Pharma have entered into a Memorandum of Understanding (MoU) with an overseas technology provider for in-licensing 7ACA technology.
Orchid Bio Pharma has been granted approval by Competent Authority under the Production Linked Incentive (PLI) Scheme for manufacturing of product 7 ACA.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
